Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Nature

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Signal Transduction and Targeted Therapy (1)
Cell Death & Disease (1)
Nature Communications (1)
Nature Chemical Biology (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (4)

Subject Check one or more subjects to show results from those subjects only.

Cancer
Cell biology
Chemical biology
Diseases
Drug discovery
Molecular biology
Oncology

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–4 of 4 results

Advanced filters: Author: Niklas Gremke Clear advanced filters

mTOR-driven autophagy suppression defines metabolic vulnerability in CDK4/6 inhibitor-resistant HR⁺/HER2⁻ breast cancer

Luise von Wichert
Alina Stroh
Niklas Gremke
ResearchOpen Access19 Feb 2026
Cell Death & Disease

P: 1-13
mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability

mTORC1 is a key mediator of drug resistance and also regulates autophagy. In this study, the authors demonstrate that cancer cells with acquired drug resistance exibit metabolic vulnerabilities mediated by high levels of mTORC1 and the consequent inhibition of autophagy.

Niklas Gremke
Pierfrancesco Polo
Thorsten Stiewe
ResearchOpen Access17 Sept 2020
Nature Communications

Volume: 11, P: 1-15
CRISPR-Cas9–based target validation for p53-reactivating model compounds

CRISPR-Cas9 based target validation revealed that the sensitivity of the p53-reactivating compound RITA is independent of functional p53 and is reliant on the regulation of the DNA damage-activated Fanconi anemia pathway.

Michael Wanzel
Jonas B Vischedyk
Thorsten Stiewe
Research23 Nov 2015
Nature Chemical Biology

Volume: 12, P: 22-28
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs

Niklas Gremke
Isabelle Besong
Thorsten Stiewe
ResearchOpen Access21 Mar 2025
Signal Transduction and Targeted Therapy

Volume: 10, P: 1-19

Search

Search articles by subject, keyword or author

Show results from

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

Nature.com

nature.com sitemap

About Nature Portfolio

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
protocols.io
Nature Index

Publishing policies

Nature portfolio policies
Open access

Author & Researcher services

Reprints & permissions
Research data
Language editing
Scientific editing
Nature Masterclasses
Research Solutions

Libraries & institutions

Librarian service & tools
Librarian portal
Open research
Recommend to library

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Professional development

Nature Awards
Nature Careers
Nature Conferences

Regional websites

Nature Africa
Nature China
Nature India
Nature Japan
Nature Middle East

Privacy Policy
Use of cookies
Legal notice
Accessibility statement
Terms & Conditions
Your US state privacy rights

© 2026 Springer Nature Limited